awmsg logo



dupilumab (Dupixent®)


Reference No. 4089

Publication date:
29/11/2019


Appraisal information

dupilumab (Dupixent®) 300 mg solution for injection
dupilumab (Dupixent®) 200 mg solution for injection


Company: Sanofi
BNF category: Skin
NMG meeting date: 09/10/2019
AWMSG meeting date: 13/11/2019
   
   
Submission Type: Limited Submission
Status: Recommended with restrictions
Advice No: 1419
Ratification by Welsh Government: 28/11/2019

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

Dupilumab (Dupixent®) is recommended as an option for restricted use within NHS Wales. Dupilumab (Dupixent®) is licensed for the treatment of moderate-to-severe atopic dermatitis in adolescents ≥ 12 to < 18 years who are candidates for systemic therapy. Dupilumab (Dupixent®) is restricted for the treatment of moderate-to-severe atopic dermatitis in adolescents ≥ 12 to < 18 years who are candidates for systemic therapy, only if the disease has not responded to at least one other systemic therapy, or these are contraindicated or not tolerated. Dupilumab (Dupixent®) is not recommended for use within NHS Wales outside of this subpopulation. This recommendation applies only in circumstances where the approved Patient Access Scheme (PAS) is utilised or where the list/contract price is equivalent or lower than the PAS price.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download